PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16082080-2	2005	We hypothesized that combining low-dose FK506 with anti-CD40 Ligand (anti-CD40L mAb) would enhance regeneration through peripheral nerve allografts while preserving immune unresponsiveness.	Tacrolimus	40-45	CD40 ligand	Mus musculus	74-79	
16470176-0	2006	FK506 controls CD40L-induced systemic autoimmunity in mice.	Tacrolimus	0-5	CD40 ligand	Mus musculus	15-20	
16470176-4	2006	Interestingly, FK506-treated CD40L tg mice showed significantly reduced autoimmune dermatitis scores and markedly decreased numbers of lesional infiltrating leukocytes.	Tacrolimus	15-20	CD40 ligand	Mus musculus	29-34	
16470176-6	2006	Furthermore, FK506 suppressed the development of cytotoxic/autoreactive CD8(+) T cells as evidenced by the reduced expression of T cell activation markers in treated CD40L tg mice.	Tacrolimus	13-18	CD40 ligand	Mus musculus	166-171	
16470176-7	2006	Importantly, FK506 induced a significant reduction in autoantibody titers in the serum of CD40L tg animals.	Tacrolimus	13-18	CD40 ligand	Mus musculus	90-95	
16470176-8	2006	As CD40L tg mice develop nephritis leading to loss of renal function proteinuria was determined after FK506 injections.	Tacrolimus	102-107	CD40 ligand	Mus musculus	3-8	
16470176-9	2006	Notably, FK506 treatment re-established renal function as indicated by significantly reduced uric protein concentrations of treated CD40L tg mice.	Tacrolimus	9-14	CD40 ligand	Mus musculus	132-137	
16470176-10	2006	Together, these findings show the beneficial therapeutic effects of FK506 for the treatment of CD40L-induced autoimmunity.	Tacrolimus	68-73	CD40 ligand	Mus musculus	95-100	
16082080-5	2005	RESULTS: Animals receiving low-dose FK506 with anti-CD40L mAb exhibited robust nerve regeneration comparable to the isograft and high-dose FK506 allograft groups.	Tacrolimus	36-41	CD40 ligand	Mus musculus	52-57	
16082080-6	2005	Nerve density was significantly increased in the low-dose FK506 with anti-CD40L mAb group compared to animals receiving anti-CD40L mAb alone (p < 0.05).	Tacrolimus	58-63	CD40 ligand	Mus musculus	74-79	
16082080-10	2005	CONCLUSION: When combined with anti-CD40L mAb, low-dose FK506 enhances nerve regeneration without disrupting immune unresponsiveness.	Tacrolimus	56-61	CD40 ligand	Mus musculus	36-41	
12409674-6	2002	RESULTS: Cyclosporine, tacrolimus, and anti-IL-2R monoclonal antibody therapy abrogated the effect of a single-dose protocol of anti-CD154 therapy.	Tacrolimus	23-33	CD40 ligand	Mus musculus	133-138	
12100723-9	2002	FK506, a calcineurin inhibitor, and nifedipine, a calcium channel inhibitor, inhibited not only the expression of TNF-alpha and CD40L, but also the up-regulation of CD80 on irradiated A20-HL cells.	Tacrolimus	0-5	CD40 ligand	Mus musculus	128-133